An Australian stem cell and regenerative medicine company

November 22, 2017

H.C. Wainwright & Co. Research Update: “First Cohort Enrollment Completed in CYP-001 Clinical Trial; Reiterate Buy”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50

October 10, 2017

Van Leeuwenhoeck Institute updates equity analyst coverage

View Report

Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share. This represents a substantial upside from the current share price

September 10, 2017

H.C. Wainwright & Co. Research Update: “Upcoming Milestones Could Prove Transformative; Reiterate Buy and Raising Target to A$1.50”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published new research on Cynata: “Raising price target—anticipating further milestones near-term. We believe that Cynata is entering a catalyst-rich period, with the possible option exercise near-term in its arrangement with Fujifilm...”

July 24, 2017

NDF’s Stuart Roberts Initiates Cynata Research Coverage

View Report

With 11 reasons to consider Cynata Therapeutics and an expected total share holder return of 331%, NDF sees a price target of $2.00 per share based on a probability-weighted valuation model.

June 06, 2017

Van Leeuwenhoeck Institute initiates equity analyst coverage

View Report

Based on NPV based valuation, we believe that Cynata Therapeutics is substantially undervalued at the current share price of AUD 0.57. Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share

More Information:  http://www.leeuwenhoeck.com